What type of study is this?

Apixaban for Extended Treatment of Provoked Venous Thromboembolism

View Full Paper

Ask AI

Bookmark

Apixaban significantly reduced the risk of symptomatic recurrent VTE compared to placebo, lowering occurrences to 1.3%.
The primary efficacy outcome showed that only 4 patients experienced recurrent VTE in the apixaban group, compared to 30 in the placebo group, indicating strong treatment effectiveness.
Participants received either apixaban or placebo for 12 months in a double-blind, randomized trial assessing outcomes like recurrent VTE and major bleeding.
This study supports the use of low-intensity apixaban therapy for patients with provoked VTE, with minimal risk of major bleeding involved.

No takes yet. Share an insight, caveat, or question.

Randomized trial reduced symptomatic recurrent VTE by 9% in patients treated with apixaban, suggesting a positive impact on anticoagulation duration.

Piazza et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial reduced symptomatic recurrent VTE by 9% in patients treated with apixaban, suggesting a positive impact on anticoagulation duration.